Home » Ciphergen Misses Nasdaq Delisting Deadline, But Investors Remain Patient

Ciphergen Misses Nasdaq Delisting Deadline, But Investors Remain Patient

Jul 14, 2006
Premium

Investors are stuck on Ciphergen.

The ProteinChip developer missed a June 23 deadline to lift its market capitalization above the Nasdaq Exchange's minimum requirements, and it now faces the prospect of being delisted.

But shares in Ciphergen have been up 6.2 percent year to date, and up 4.3 percent since May 31, when the company disclosed that its market cap had fallen below the Nasdaq's minimum standard of $50 million for 10 consecutive trading days.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

UK Bioethics Group Gives Cautious OK for Genetically Modifying Human Embryos

The UK's Nuffield Council on Bioethics says genetically modifying human embryos could be morally permissible, according to the Guardian.

CRISPR-Induced Damage?

A new Nature Biotechnology paper reports that CRISPR-Cas9 gene editing can lead to large deletions or complex rearrangements that could be pathogenic.

'Fax' It Over

The Wall Street Journal likens a prototype developed by Synthetic Genomics to a "biological fax machine."

This Week in PNAS

In PNAS this week: strategy for reactivating Rett syndrome-linked MECP2, small molecules able to suppress Staphylococcus aureus virulence, and more.

Aug
23
Featured Webinar

Automated High-Throughput Protein Production of Human Proteins and Antibodies

Sponsored by
Tecan

This webinar will discuss an automated, high-throughput method of generating high-quality antigens and antibodies.

What's Popular?

In Proteomics & Protein Research

  1. Harvard Team Combines SNP-Seq, FREP to Identify Non-Coding Functional SNPs

  2. Somalogic Licenses GNS Healthcare Machine Learning Tech

  3. FAIMS Could Enable Deep Proteome Coverage Without Fractionation, UW Team Finds

    Premium

  4. Bruker Acquires German Microscopy Specialist JPK Instruments

  5. Omic, Microscopic Analysis Elucidates Otzi's Last Meal

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2018 GenomeWeb LLC.  All Rights Reserved.